Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cytomegalovirus is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella zoster virus (which causes chicken pox), and Epstein Barr virus (which causes infectious mononucleosis). These viruses share a characteristic ability to remain dormant within the body over a long period. CMV viral genes are co-ordinately expressed in groups at various times after infection. Early viral proteins are expressed in the nucleus of infected cells within 3 to 24 hours of infection prior to the commencement of viral DNA replication. This is followed by expression of the early intermediate genes, which encode enzymes required for viral DNA replication. After 48 to 72 hours, a number of late viral antigens may be demonstrated in the nuclei and cytoplasm of infected cells. pp65 is a 65kD phosphorylated glycoprotein and is the most abundant of the late antigens.
Loading...
| CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
| TCR-L138 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#1), pCDTCR1 | CMV | TCRCD8-CMV#1 | Human | PLKMLNIPSINVHHYPSAAERKH | HLA-B3501 | Lentiviral | |
| TCR-L139 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#4), pCDTCR1 | CMV | TCRCD8-CMV#4 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L140 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#8), pCDTCR1 | CMV | TCRCD8-CMV#8 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L141 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#9), pCDTCR1 | CMV | TCRCD8-CMV#9 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L142 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#10), pCDTCR1 | CMV | TCRCD8-CMV#10 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L143 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#11), pCDTCR1 | CMV | TCRCD8-CMV#11 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L144 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#12), pCDTCR1 | CMV | TCRCD8-CMV#12 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L145 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#14), pCDTCR1 | CMV | TCRCD8-CMV#14 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L146 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#15), pCDTCR1 | CMV | TCRCD8-CMV#15 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L147 | Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#16), pCDTCR1 | CMV | TCRCD8-CMV#16 | Human | NLVPMVATV | HLA-A0201 | Lentiviral | |
| TCR-L148 | Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#1), pCDTCR1 | CMV | TCRCD4-CMV#1 | Human | PLKMLNIPSINVHHYPSAAERKH | HLA-DRB1*0701 | Lentiviral | |
| TCR-L149 | Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#3), pCDTCR1 | CMV | TCRCD4-CMV#3 | Human | VELRQYDPVAALFFFDIDLLLQR | HLA-DRB1*0701 | Lentiviral | |
| TCR-L150 | Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#5), pCDTCR1 | CMV | TCRCD4-CMV#5 | Human | VELRQYDPVAALFFFDIDLLLQR | HLA-DRB1*0701 | Lentiviral |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
